Does the media prefer KROS or EDSA?

In the previous week, Keros Therapeutics had 14 more articles in the media than Edesa Biotech. MarketBeat recorded 17 mentions for Keros Therapeutics and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.93 beat Keros Therapeutics' score of 0.32 indicating that Edesa Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, GALT or EDSA?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is GALT or EDSA more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Edesa Biotech N/A -286.52% -75.36%

Which has stronger valuation & earnings, GLSI or EDSA?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is GLSI or EDSA more profitable?

Edesa Biotech's return on equity of -286.52% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -833.03% -317.44% Edesa Biotech N/A -286.52% -75.36%

Does the media prefer GLSI or EDSA?

In the previous week, Greenwich LifeSciences had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 3 mentions for Edesa Biotech. Greenwich LifeSciences' average media sentiment score of 1.17 beat Edesa Biotech's score of 0.93 indicating that Greenwich LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RNA or EDSA more profitable?

Avidity Biosciences' return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Avidity Biosciences N/A N/A N/A Edesa Biotech N/A -286.52% -75.36%

Does the media refer more to RNA or EDSA?

In the previous week, Avidity Biosciences had 10 more articles in the media than Edesa Biotech. MarketBeat recorded 13 mentions for Avidity Biosciences and 3 mentions for Edesa Biotech. Avidity Biosciences' average media sentiment score of 1.02 beat Edesa Biotech's score of 0.93 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LUCD or EDSA?

In the previous week, Lucid Diagnostics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 4 mentions for Lucid Diagnostics and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.93 beat Lucid Diagnostics' score of 0.25 indicating that Edesa Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Edesa Biotech (EDSA) Competitors

$5.30 -0.22 (-3.99%)

Closing price 08/12/2026 04:00 PM Eastern

Extended Trading

$5.32 +0.02 (+0.36%)

As of 04:01 AM Eastern

Compare

EDSA vs. KROS, GALT, GLSI, RNA, and LUCD

Should you buy Edesa Biotech stock or one of its competitors? Edesa Biotech's main competitors and comparable companies include Keros Therapeutics (KROS), Galectin Therapeutics (GALT), Greenwich LifeSciences (GLSI), Avidity Biosciences (RNA), and Lucid Diagnostics (LUCD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Edesa Biotech compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Keros Therapeutics has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

In the previous week, Keros Therapeutics had 14 more articles in the media than Edesa Biotech. MarketBeat recorded 17 mentions for Keros Therapeutics and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.93 beat Keros Therapeutics' score of 0.32 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Keros Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Edesa Biotech has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Edesa Biotech	N/A	-286.52%	-75.36%

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Keros Therapeutics currently has a consensus target price of $20.50, indicating a potential upside of 83.04%. Edesa Biotech has a consensus target price of $5.00, indicating a potential downside of 5.66%. Given Keros Therapeutics' higher probable upside, research analysts plainly believe Keros Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Keros Therapeutics beats Edesa Biotech on 9 of the 16 factors compared between the two stocks.

How does Edesa Biotech compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, Edesa Biotech had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 3 mentions for Edesa Biotech and 1 mentions for Galectin Therapeutics. Edesa Biotech's average media sentiment score of 0.93 beat Galectin Therapeutics' score of 0.62 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Galectin Therapeutics	Positive
Edesa Biotech	Positive

Galectin Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 250.32%. Edesa Biotech has a consensus target price of $5.00, indicating a potential downside of 5.66%. Given Galectin Therapeutics' higher probable upside, research analysts clearly believe Galectin Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Galectin Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Edesa Biotech	N/A	-286.52%	-75.36%

Galectin Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Summary

Edesa Biotech beats Galectin Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Edesa Biotech compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Greenwich LifeSciences presently has a consensus price target of $57.00, suggesting a potential upside of 236.88%. Edesa Biotech has a consensus price target of $5.00, suggesting a potential downside of 5.66%. Given Greenwich LifeSciences' higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Greenwich LifeSciences has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

In the previous week, Greenwich LifeSciences had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 3 mentions for Edesa Biotech. Greenwich LifeSciences' average media sentiment score of 1.17 beat Edesa Biotech's score of 0.93 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edesa Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edesa Biotech's return on equity of -286.52% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-833.03%	-317.44%
Edesa Biotech	N/A	-286.52%	-75.36%

Summary

Edesa Biotech beats Greenwich LifeSciences on 8 of the 14 factors compared between the two stocks.

How does Edesa Biotech compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Avidity Biosciences' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
Edesa Biotech	N/A	-286.52%	-75.36%

Avidity Biosciences currently has a consensus target price of $63.85, suggesting a potential upside of 424.62%. Edesa Biotech has a consensus target price of $5.00, suggesting a potential downside of 5.66%. Given Avidity Biosciences' higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

5.5% of Edesa Biotech shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by company insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Edesa Biotech has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.68	-$16.59M	-$0.97	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

In the previous week, Avidity Biosciences had 10 more articles in the media than Edesa Biotech. MarketBeat recorded 13 mentions for Avidity Biosciences and 3 mentions for Edesa Biotech. Avidity Biosciences' average media sentiment score of 1.02 beat Edesa Biotech's score of 0.93 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edesa Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Avidity Biosciences beats Edesa Biotech on 8 of the 13 factors compared between the two stocks.

How does Edesa Biotech compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Edesa Biotech has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Edesa Biotech	N/A	-286.52%	-75.36%

Edesa Biotech has lower revenue, but higher earnings than Lucid Diagnostics. Edesa Biotech is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	42.44	-$58.01M	-$0.47	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Lucid Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Lucid Diagnostics presently has a consensus price target of $4.19, indicating a potential upside of 325.39%. Edesa Biotech has a consensus price target of $5.00, indicating a potential downside of 5.66%. Given Lucid Diagnostics' higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Lucid Diagnostics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 4 mentions for Lucid Diagnostics and 3 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.93 beat Lucid Diagnostics' score of 0.25 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lucid Diagnostics beats Edesa Biotech on 8 of the 15 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDSA vs. The Competition

Export

Metric	Edesa Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$53.17M	$3.74B	$7.08B	$12.88B
Dividend Yield	N/A	3.76%	2.58%	10.74%
P/E Ratio	-3.96	10.36	268.54	25.09
Price / Sales	N/A	1,271.02	592.89	85.19
Price / Cash	N/A	102.94	70.59	50.58
Price / Book	11.78	17.82	13.14	6.23
Net Income	-$7.19M	-$13.23M	$3.45B	$347.40M
7 Day Performance	4.95%	3.03%	1.82%	1.35%
1 Month Performance	-22.17%	1.45%	0.91%	0.51%
1 Year Performance	142.01%	55.46%	67.71%	18.99%

Edesa Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDSA Edesa Biotech	1.9686 of 5 stars	$5.30 -4.0%	$5.00 -5.7%	+144.2%	$53.17M	N/A	N/A	20	Upcoming Earnings
KROS Keros Therapeutics	3.8605 of 5 stars	$10.25 +1.4%	$20.50 +100.0%	-18.3%	$200.10M	$244.06M	N/A	100	Gap Down
GALT Galectin Therapeutics	1.83 of 5 stars	$2.99 -1.3%	$11.00 +267.9%	-16.7%	$199.55M	N/A	N/A	9
GLSI Greenwich LifeSciences	3.3156 of 5 stars	$14.36 +6.0%	$57.00 +297.0%	+37.0%	$198.74M	N/A	N/A	3	Positive News Earnings Report
RNA Avidity Biosciences	2.3235 of 5 stars	$11.54 +1.9%	$67.60 +485.8%	-73.7%	$197.40M	$36.68M	N/A	190	Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDSA) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edesa Biotech (EDSA) Competitors

EDSA vs. KROS, GALT, GLSI, RNA, and LUCD

How does Edesa Biotech compare to Keros Therapeutics?

Summary

How does Edesa Biotech compare to Galectin Therapeutics?

Summary

How does Edesa Biotech compare to Greenwich LifeSciences?

Summary

How does Edesa Biotech compare to Avidity Biosciences?

Summary

How does Edesa Biotech compare to Lucid Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edesa Biotech (EDSA) Competitors

EDSA vs. KROS, GALT, GLSI, RNA, and LUCD

How does Edesa Biotech compare to Keros Therapeutics?

Which has higher earnings and valuation, KROS or EDSA?

Does the media prefer KROS or EDSA?

Which has more risk and volatility, KROS or EDSA?

Is KROS or EDSA more profitable?

Do insiders & institutionals believe in KROS or EDSA?

Do analysts recommend KROS or EDSA?

Summary

How does Edesa Biotech compare to Galectin Therapeutics?

Does the media prefer GALT or EDSA?

Do analysts rate GALT or EDSA?

Is GALT or EDSA more profitable?

Which has more risk and volatility, GALT or EDSA?

Do insiders and institutionals have more ownership in GALT or EDSA?

Which has preferable valuation and earnings, GALT or EDSA?

Summary

How does Edesa Biotech compare to Greenwich LifeSciences?

Which has stronger valuation & earnings, GLSI or EDSA?

Do insiders & institutionals have more ownership in GLSI or EDSA?

Do analysts rate GLSI or EDSA?

Which has more risk & volatility, GLSI or EDSA?

Does the media prefer GLSI or EDSA?

Is GLSI or EDSA more profitable?

Summary

How does Edesa Biotech compare to Avidity Biosciences?

Is RNA or EDSA more profitable?

Do analysts rate RNA or EDSA?

Do institutionals and insiders have more ownership in RNA or EDSA?

Which has better earnings and valuation, RNA or EDSA?

Does the media refer more to RNA or EDSA?

Summary

How does Edesa Biotech compare to Lucid Diagnostics?

Is LUCD or EDSA more profitable?

Which has higher earnings & valuation, LUCD or EDSA?

Which has more risk & volatility, LUCD or EDSA?

Do analysts prefer LUCD or EDSA?

Do institutionals & insiders have more ownership in LUCD or EDSA?

Does the media prefer LUCD or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools